Evaluation of left ventricular function using 3D and speckle tracking echocardiography in breast cancer patients following treatment with anthracycline and trastuzumab
Main Article Content
Abstract
Adjuvant therapy combining anthracyclines and trastuzumab in breast cancer patients can cause cardiotoxicity, resulting in higher mortality rates. This study aimed to assess left ventricular (LV) function using 3D echocardiography and speckle tracking echocardiography in breast cancer patients after anthracycline and trastuzumab treatment. The study included 20 female breast cancer patients. The average LV ejection fraction (LVEF) measured by 3D echocardiography was 60.75 ± 7.61%. A decrease in 3D-LVEF to below 50% was seen in 5% of the patients (n = 1). Impaired left ventricular global longitudinal strain (GLS > -19%) was found in 11 patients (55%). Additionally, left ventricular diastolic dysfunction was present in 25% of the group. The only case with an LVEF < 50% was in a patient aged ≥ 50 who underwent surgery and was observed at the 6-month follow-up; however, no significant association could be established due to the small sample size. Three-dimensional and speckle tracking echocardiography provide valuable insights to evaluate left ventricular dysfunction in breast cancer patients receiving anthracycline and trastuzumab therapy.
Article Details
Keywords
Breast cancer, left ventricular function, 3D echocardiography, Anthracycline, Trastuzumab
References
2. Seidman, Andrew, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of clinical oncology. 2002; 20(5): 1215-1221. doi: 10.1200/JCO.2002.20.5.1215.
3. Chen J, et al. Early detection of cardiotoxicity by 3D speckle tracking imaging of area strain in breast cancer patients receiving chemotherapy. Echocardiography. 2019; 36(9): 1682-1688. https://doi.org/10.1111/echo.14467.
4. Lang, Roberto M, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging. 2015; 16(3): 233-271. https://doi.org/10.1093/ehjci/jev014.
5. Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022; 43(41): 4229-4361. https://doi.org/10.1093/eurheartj/ehac244.
6. Phùng Thị Huyền. Đánh giá kết quả hóa trị bổ trợ kết hợp Trastuzumab trên bệnh nhân ung thư vú giai đoạn II, III. Luận văn Tiến sĩ y học, Trường Đại học Y Hà Nội; 2016.
7. Aladwani, Afrah, et al. Comparing trastuzumab-related cardiotoxicity between elderly and younger patients with breast cancer: a prospective cohort study. European review for medical and pharmacological sciences. 2021; 25(24): 7643-7653.
8. Nguyễn Thái Sơn. Đánh giá kết quả hóa trị bổ trợ kết hợp Trastuzumab trên bệnh nhân ung thư vú giai đoạn II - III tại bệnh viện ung bướu Hà Nội. Luận văn chuyên khoa cấp II, Trường Đại học Y Hà Nội; 2020.
9. Bloom, Michelle W, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circulation: Heart Failure. 2016; 9(1): e002661. https://doi.org/10.1161/circheartfailure.115.002661.
10. Fallah-Rad, Nazanin, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. Journal of the American College of Cardiology. 2011; 57(22): 2263-2270. doi:10.1016/j.jacc.2010.11.063.
11. Bouwer, Nathalie I., et al. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. The Breast. 2020; 52: 33-44. doi: 10.1016/j.breast.2020.04.005.
12. Sawaya, Heloisa, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circulation: Cardiovascular Imaging. 2012; 5(5): 596-603. doi: 10.1161/circimaging.112.973321.
13. Bowles, Erin J Aiello, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. Journal of the National Cancer Institute. 2012; 104(17): 1293-1305. doi: 10.1093/jnci/djs317.
14. Moran M S. Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831: Halyard MY, Pisansky TM, Dueck AC, et al (Mayo Clinic Scottsdale, AZ; Mayo Clinic and Mayo Foundation, Rochester, MN; Southwest Oncology Group Operations Office, San Antonio, TX; et al) J Clin Oncol 27: 2638-2644, 2009. Breast Diseases: A Year Book Quarterly. 2010; 21(3): 277-278. doi: 10.1200/JCO.2008.17.9549.
15. Fiúza Manuela. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Advances in therapy. 2009; 26. Suppl 1:9-17. doi: 10.1007/s12325-009-0048-z.
16. Keefe, Deborah L. Trastuzumab-associated cardiotoxicity. Cancer. 2002; 95(7): 1592-1600. doi: 10.1002/cncr.10854.
17. Perez, Edith A, et al. Clinical cardiac tolerability of trastuzumab. Journal of Clinical Oncology. 2004; 22(2): 322-329. doi: 10.1200/JCO.2004.01.12.